-+ 0.00%
-+ 0.00%
-+ 0.00%

Janux doses first patient in Phase 1 trial of JANX013 in metastatic prostate cancer

PUBT·09/14/2026 12:03:55
Listen to the news
Janux doses first patient in Phase 1 trial of JANX013 in metastatic prostate cancer
  • Janux Therapeutics dosed the first patient in a Phase 1 trial of JANX013 for metastatic castration-resistant prostate cancer.
  • Results have not been presented; the study will generate initial safety, drug-behavior, immune-activity, and early efficacy readouts.
  • Trial tests JANX013 with JANX007, aiming to strengthen and prolong anti-tumor immune responses through tumor-restricted CD28 co-stimulation.
  • Program expands Janux’s PSMA-focused prostate cancer strategy, with plans to study JANX013 alongside other portfolio candidates over time.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Janux Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609140800BIZWIRE_USPR_____20260914_BW249735) on September 14, 2026, and is solely responsible for the information contained therein.